109 related articles for article (PubMed ID: 34318617)
1. Combined tumor epithelial and stromal histopathology with keratin 81 expression predicts prognosis for pancreatic ductal adenocarcinoma.
Park E; Yoo JE; Hwang HK; Kang CM; Lee CK; Kim MH; Bang S; Park YN
J Hepatobiliary Pancreat Sci; 2022 Feb; 29(2):250-261. PubMed ID: 34318617
[TBL] [Abstract][Full Text] [Related]
2. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
3. Stroma composition and proliferative activity are related to therapy response in neoadjuvant treated pancreatic ductal adenocarcinoma.
Haeberle L; Cacciato Insilla A; Kapp AC; Steiger K; Schlitter AM; Konukiewitz B; Demir IE; Friess H; Esposito I
Histol Histopathol; 2021 Jul; 36(7):733-742. PubMed ID: 33769550
[TBL] [Abstract][Full Text] [Related]
4. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis.
Yin L; Pu N; Thompson E; Miao Y; Wolfgang C; Yu J
Clin Cancer Res; 2021 Feb; 27(3):740-748. PubMed ID: 33082211
[TBL] [Abstract][Full Text] [Related]
5. Stroma vs epithelium-enhanced prognostics through histologic stratification in pancreatic ductal adenocarcinoma.
Kalloger SE; Karasinska JM; Keung MS; Thompson DL; Ho J; Chow C; Gao D; Topham JT; Warren C; Wong HL; Lee MK; Renouf DJ; Schaeffer DF
Int J Cancer; 2021 Jan; 148(2):481-491. PubMed ID: 32955725
[TBL] [Abstract][Full Text] [Related]
6. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
[TBL] [Abstract][Full Text] [Related]
7. Identification and Validation of Immune Molecular Subtypes in Pancreatic Ductal Adenocarcinoma: Implications for Prognosis and Immunotherapy.
Li R; He Y; Zhang H; Wang J; Liu X; Liu H; Wu H; Liang Z
Front Immunol; 2021; 12():690056. PubMed ID: 34335594
[TBL] [Abstract][Full Text] [Related]
8. Combination of KRAS and SMAD4 mutations in formalin-fixed paraffin-embedded tissues as a biomarker for pancreatic cancer.
Yokose T; Kitago M; Matsuda S; Sasaki Y; Masugi Y; Nakamura Y; Shinoda M; Yagi H; Abe Y; Oshima G; Hori S; Yusuke F; Nakano Y; Endo Y; Abe K; Tokino T; Kitagawa Y
Cancer Sci; 2020 Jun; 111(6):2174-2182. PubMed ID: 32314446
[TBL] [Abstract][Full Text] [Related]
9. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
10. The Roles of Frequently Mutated Genes of Pancreatic Cancer in Regulation of Tumor Microenvironment.
Sun H; Zhang B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820920969. PubMed ID: 32372692
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
[No Abstract] [Full Text] [Related]
12. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
13. Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Qian Y; Gong Y; Fan Z; Luo G; Huang Q; Deng S; Cheng H; Jin K; Ni Q; Yu X; Liu C
J Hematol Oncol; 2020 Oct; 13(1):130. PubMed ID: 33008426
[TBL] [Abstract][Full Text] [Related]
14. Molecular profiling of stroma highlights stratifin as a novel biomarker of poor prognosis in pancreatic ductal adenocarcinoma.
Robin F; Angenard G; Cano L; Courtin-Tanguy L; Gaignard E; Khene ZE; Bergeat D; Clément B; Boudjema K; Coulouarn C; Sulpice L
Br J Cancer; 2020 Jul; 123(1):72-80. PubMed ID: 32376891
[TBL] [Abstract][Full Text] [Related]
15. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
[TBL] [Abstract][Full Text] [Related]
16. MicroRNA-132 Plays an Independent Prognostic Role in Pancreatic Ductal Adenocarcinoma and Acts as a Tumor Suppressor.
Chen Y; Zhu H; Wang Y; Song Y; Zhang P; Wang Z; Gao J; Li Z; Du Y
Technol Cancer Res Treat; 2019 Jan; 18():1533033818824314. PubMed ID: 30803373
[TBL] [Abstract][Full Text] [Related]
17. Kindlin-2 expression in peritumoral stroma is associated with poor prognosis in pancreatic ductal adenocarcinoma.
Mahawithitwong P; Ohuchida K; Ikenaga N; Fujita H; Zhao M; Kozono S; Shindo K; Ohtsuka T; Mizumoto K; Tanaka M
Pancreas; 2013 May; 42(4):663-9. PubMed ID: 23508013
[TBL] [Abstract][Full Text] [Related]
18. Assessment of the stromal contribution to Sonic Hedgehog-dependent pancreatic adenocarcinoma.
Damhofer H; Medema JP; Veenstra VL; Badea L; Popescu I; Roelink H; Bijlsma MF
Mol Oncol; 2013 Dec; 7(6):1031-42. PubMed ID: 23998958
[TBL] [Abstract][Full Text] [Related]
19. Mutant
Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
[TBL] [Abstract][Full Text] [Related]
20. Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma.
Naso JR; Topham JT; Karasinska JM; Lee MKC; Kalloger SE; Wong HL; Nelson J; Moore RA; Mungall AJ; Jones SJM; Laskin J; Marra MA; Renouf DJ; Schaeffer DF
Cancer Med; 2021 Feb; 10(3):1155-1165. PubMed ID: 33372414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
